ZA200401598B - Integrin inhibitors for the treatment of eye diseases. - Google Patents

Integrin inhibitors for the treatment of eye diseases. Download PDF

Info

Publication number: ZA200401598B
Authority: ZA; South Africa
Prior art keywords: atoms; propionic acid; mono; alkyl; coor
Prior art date: 2001-08-01

Application number

ZA200401598A

Other languages

English (en)

Inventor

Hans Markus Bender

Ulrich Lang

Martin Friedlander

Jutta Haunschild

Matthias Wiesner

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-01

Filing date

2004-02-26

Publication date

2004-11-17

2004-02-26 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2004-11-17 Publication of ZA200401598B publication Critical patent/ZA200401598B/en

Links

239000003112 inhibitor Substances 0.000 title claims description 50
208000030533 eye disease Diseases 0.000 title claims description 24
102000006495 integrins Human genes 0.000 title description 27
108010044426 integrins Proteins 0.000 title description 27
238000011282 treatment Methods 0.000 title description 21
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 109
125000004432 carbon atom Chemical group C* 0.000 claims description 81
238000000034 method Methods 0.000 claims description 77
125000000217 alkyl group Chemical group 0.000 claims description 59
235000019260 propionic acid Nutrition 0.000 claims description 48
150000001875 compounds Chemical class 0.000 claims description 42
125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 claims description 33
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 33
-1 Phe Chemical compound 0.000 claims description 32
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 32
125000004433 nitrogen atom Chemical group N* 0.000 claims description 24
229910052760 oxygen Inorganic materials 0.000 claims description 23
125000006367 bivalent amino carbonyl group Chemical group [H]N([*:1])C([*:2])=O 0.000 claims description 22
230000033115 angiogenesis Effects 0.000 claims description 21
125000000623 heterocyclic group Chemical group 0.000 claims description 20
150000003839 salts Chemical class 0.000 claims description 20
210000004127 vitreous body Anatomy 0.000 claims description 19
125000000753 cycloalkyl group Chemical group 0.000 claims description 18
208000002780 macular degeneration Diseases 0.000 claims description 18
239000000203 mixture Substances 0.000 claims description 17
125000004430 oxygen atom Chemical group O* 0.000 claims description 17
238000011321 prophylaxis Methods 0.000 claims description 16
125000004434 sulfur atom Chemical group 0.000 claims description 16
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
229910052717 sulfur Inorganic materials 0.000 claims description 13
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 12
108090000765 processed proteins & peptides Proteins 0.000 claims description 12
102000004196 processed proteins & peptides Human genes 0.000 claims description 11
201000010099 disease Diseases 0.000 claims description 9
229920001184 polypeptide Polymers 0.000 claims description 9
206010012689 Diabetic retinopathy Diseases 0.000 claims description 8
229910052739 hydrogen Inorganic materials 0.000 claims description 8
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 8
239000012453 solvate Substances 0.000 claims description 8
201000002563 Histoplasmosis Diseases 0.000 claims description 6
125000003710 aryl alkyl group Chemical group 0.000 claims description 6
125000003118 aryl group Chemical group 0.000 claims description 6
COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims description 5
125000004429 atom Chemical group 0.000 claims description 5
208000001491 myopia Diseases 0.000 claims description 5
230000004379 myopia Effects 0.000 claims description 5
QIVBCDIJIAJPQS-SECBINFHSA-N D-tryptophane Chemical compound C1=CC=C2C(C[C@@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-SECBINFHSA-N 0.000 claims description 4
OUYCCCASQSFEME-MRVPVSSYSA-N D-tyrosine Chemical compound OC(=O)[C@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-MRVPVSSYSA-N 0.000 claims description 4
101100241859 Mus musculus Oacyl gene Proteins 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 4
125000001624 naphthyl group Chemical group 0.000 claims description 4
229910052757 nitrogen Inorganic materials 0.000 claims description 4
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
125000006239 protecting group Chemical group 0.000 claims description 4
AILFABHHXYOJCC-UHFFFAOYSA-N 3-phenyl-3-[6-[3-(pyridin-2-ylamino)propoxy]-1h-indol-3-yl]propanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C(C1=CC=2)=CNC1=CC=2OCCCNC1=CC=CC=N1 AILFABHHXYOJCC-UHFFFAOYSA-N 0.000 claims description 3
229910006069 SO3H Inorganic materials 0.000 claims description 3
125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims description 3
229920006395 saturated elastomer Polymers 0.000 claims description 3
125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 3
PJCDJHCTQQOWHG-UHFFFAOYSA-N 3-phenyl-3-[5-[4-(pyridin-2-ylamino)butoxy]-1h-indol-3-yl]propanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C(C1=C2)=CNC1=CC=C2OCCCCNC1=CC=CC=N1 PJCDJHCTQQOWHG-UHFFFAOYSA-N 0.000 claims description 2
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 claims description 2
125000002252 acyl group Chemical group 0.000 claims description 2
125000002947 alkylene group Chemical group 0.000 claims description 2
125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
AMLYAMJWYAIXIA-VWNVYAMZSA-N cilengitide Chemical group N1C(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C(C)C)N(C)C(=O)[C@H]1CC1=CC=CC=C1 AMLYAMJWYAIXIA-VWNVYAMZSA-N 0.000 claims description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 2
125000002950 monocyclic group Chemical group 0.000 claims description 2
125000000437 thiazol-2-yl group Chemical group [H]C1=C([H])N=C(*)S1 0.000 claims description 2
125000000896 monocarboxylic acid group Chemical group 0.000 claims 9
DKROPODTCZMULC-UHFFFAOYSA-N 3-phenyl-3-[5-[3-(pyridin-2-ylamino)propoxy]-1h-indol-3-yl]propanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C(C1=C2)=CNC1=CC=C2OCCCNC1=CC=CC=N1 DKROPODTCZMULC-UHFFFAOYSA-N 0.000 claims 1
TZLNTSBSYDYOPB-UHFFFAOYSA-N 3-phenyl-3-[6-[4-(pyridin-2-ylamino)butoxy]-1h-indol-3-yl]propanoic acid Chemical compound C=1C=CC=CC=1C(CC(=O)O)C(C1=CC=2)=CNC1=CC=2OCCCCNC1=CC=CC=N1 TZLNTSBSYDYOPB-UHFFFAOYSA-N 0.000 claims 1
101100279860 Caenorhabditis elegans epg-2 gene Proteins 0.000 claims 1
208000037283 autosomal dominant myopia 11 Diseases 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
210000001508 eye Anatomy 0.000 description 30
239000002105 nanoparticle Substances 0.000 description 21
IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 17
235000002639 sodium chloride Nutrition 0.000 description 16
229920000642 polymer Polymers 0.000 description 14
239000003960 organic solvent Substances 0.000 description 12
125000001424 substituent group Chemical group 0.000 description 11
206010064930 age-related macular degeneration Diseases 0.000 description 10
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 10
239000007924 injection Substances 0.000 description 10
238000002347 injection Methods 0.000 description 10
239000005557 antagonist Substances 0.000 description 9
239000002904 solvent Substances 0.000 description 9
230000000694 effects Effects 0.000 description 8
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
238000002513 implantation Methods 0.000 description 7
239000000243 solution Substances 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
239000004480 active ingredient Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
239000003446 ligand Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
206010029113 Neovascularisation Diseases 0.000 description 5
108010031318 Vitronectin Proteins 0.000 description 5
102100035140 Vitronectin Human genes 0.000 description 5
239000007864 aqueous solution Substances 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
239000003814 drug Substances 0.000 description 5
239000002502 liposome Substances 0.000 description 5
239000008188 pellet Substances 0.000 description 5
238000005185 salting out Methods 0.000 description 5
239000000725 suspension Substances 0.000 description 5
102000003974 Fibroblast growth factor 2 Human genes 0.000 description 4
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 4
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
102100022337 Integrin alpha-V Human genes 0.000 description 4
241001465754 Metazoa Species 0.000 description 4
108010048673 Vitronectin Receptors Proteins 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
208000035475 disorder Diseases 0.000 description 4
238000006073 displacement reaction Methods 0.000 description 4
238000009472 formulation Methods 0.000 description 4
GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 4
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
239000002245 particle Substances 0.000 description 4
229920002338 polyhydroxyethylmethacrylate Polymers 0.000 description 4
238000002360 preparation method Methods 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
238000002560 therapeutic procedure Methods 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
208000010412 Glaucoma Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
241000283973 Oryctolagus cuniculus Species 0.000 description 3
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
210000004087 cornea Anatomy 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000003993 interaction Effects 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
239000012071 phase Substances 0.000 description 3
229920001610 polycaprolactone Polymers 0.000 description 3
238000013268 sustained release Methods 0.000 description 3
239000012730 sustained-release form Substances 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108090000695 Cytokines Proteins 0.000 description 2
102000004127 Cytokines Human genes 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
108010067306 Fibronectins Proteins 0.000 description 2
102000016359 Fibronectins Human genes 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
229920000954 Polyglycolide Polymers 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
102000019997 adhesion receptor Human genes 0.000 description 2
108010013985 adhesion receptor Proteins 0.000 description 2
238000013019 agitation Methods 0.000 description 2
238000013459 approach Methods 0.000 description 2
108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
229920000249 biocompatible polymer Polymers 0.000 description 2
238000005266 casting Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
238000001704 evaporation Methods 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
230000004438 eyesight Effects 0.000 description 2
229940126864 fibroblast growth factor Drugs 0.000 description 2
229920002674 hyaluronan Polymers 0.000 description 2
229960003160 hyaluronic acid Drugs 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
239000004310 lactic acid Substances 0.000 description 2
235000014655 lactic acid Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000014399 negative regulation of angiogenesis Effects 0.000 description 2
239000007764 o/w emulsion Substances 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
229920000747 poly(lactic acid) Polymers 0.000 description 2
239000004632 polycaprolactone Substances 0.000 description 2
229920000728 polyester Polymers 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000008569 process Effects 0.000 description 2
238000011002 quantification Methods 0.000 description 2
239000002464 receptor antagonist Substances 0.000 description 2
229940044551 receptor antagonist Drugs 0.000 description 2
210000001525 retina Anatomy 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000002691 unilamellar liposome Substances 0.000 description 2
230000004393 visual impairment Effects 0.000 description 2
JTTHKOPSMAVJFE-SECBINFHSA-N (2r)-2-azaniumyl-4-phenylbutanoate Chemical compound [O-]C(=O)[C@H]([NH3+])CCC1=CC=CC=C1 JTTHKOPSMAVJFE-SECBINFHSA-N 0.000 description 1
229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
OZSRHFORCGVPJI-UHFFFAOYSA-N 2-(butylsulfonylamino)propanoic acid Chemical compound CCCCS(=O)(=O)NC(C)C(O)=O OZSRHFORCGVPJI-UHFFFAOYSA-N 0.000 description 1
MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
IGEIFKIBAFHEFY-UHFFFAOYSA-N 2-[(2,4,6-trimethylphenyl)sulfonylamino]propanoic acid Chemical compound OC(=O)C(C)NS(=O)(=O)C1=C(C)C=C(C)C=C1C IGEIFKIBAFHEFY-UHFFFAOYSA-N 0.000 description 1
ODOMGNRHMFPUEP-UHFFFAOYSA-N 3-(2,1,3-benzothiadiazol-5-yl)-3-[6-[2-[6-(methylamino)pyridin-2-yl]ethoxy]-1h-indol-3-yl]propanoic acid Chemical compound CNC1=CC=CC(CCOC=2C=C3NC=C(C3=CC=2)C(CC(O)=O)C2=CC3=NSN=C3C=C2)=N1 ODOMGNRHMFPUEP-UHFFFAOYSA-N 0.000 description 1
JPZXHKDZASGCLU-GFCCVEGCSA-N 3-(2-Naphthyl)-D-Alanine Chemical compound C1=CC=CC2=CC(C[C@@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-GFCCVEGCSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
102000009027 Albumins Human genes 0.000 description 1
108010088751 Albumins Proteins 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003210 Arteriosclerosis Diseases 0.000 description 1
201000004569 Blindness Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000499489 Castor canadensis Species 0.000 description 1
206010008190 Cerebrovascular accident Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
208000011231 Crohn disease Diseases 0.000 description 1
102000001189 Cyclic Peptides Human genes 0.000 description 1
108010069514 Cyclic Peptides Proteins 0.000 description 1
ZGUNAGUHMKGQNY-SSDOTTSWSA-N D-alpha-phenylglycine Chemical compound OC(=O)[C@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-SSDOTTSWSA-N 0.000 description 1
CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 description 1
229930182832 D-phenylalanine Natural products 0.000 description 1
229930182827 D-tryptophan Natural products 0.000 description 1
229930195709 D-tyrosine Natural products 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
108010049003 Fibrinogen Proteins 0.000 description 1
102000008946 Fibrinogen Human genes 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 1
206010061216 Infarction Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108010028750 Integrin-Binding Sialoprotein Proteins 0.000 description 1
102000016921 Integrin-Binding Sialoprotein Human genes 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
125000000998 L-alanino group Chemical group [H]N([*])[C@](C([H])([H])[H])([H])C(=O)O[H] 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical group CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
102000007547 Laminin Human genes 0.000 description 1
108010085895 Laminin Proteins 0.000 description 1
206010025421 Macule Diseases 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
REYJJPSVUYRZGE-UHFFFAOYSA-N Octadecylamine Chemical compound CCCCCCCCCCCCCCCCCCN REYJJPSVUYRZGE-UHFFFAOYSA-N 0.000 description 1
208000001132 Osteoporosis Diseases 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical class [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 1
101000781681 Protobothrops flavoviridis Disintegrin triflavin Proteins 0.000 description 1
201000004681 Psoriasis Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
239000004809 Teflon Substances 0.000 description 1
229920006362 Teflon® Polymers 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
108060008245 Thrombospondin Proteins 0.000 description 1
102000002938 Thrombospondin Human genes 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
150000001413 amino acids Chemical group 0.000 description 1
238000002399 angioplasty Methods 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
208000011775 arteriosclerosis disease Diseases 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000008827 biological function Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
210000005252 bulbus oculi Anatomy 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
230000004456 color vision Effects 0.000 description 1
201000000159 corneal neovascularization Diseases 0.000 description 1
238000009295 crossflow filtration Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
238000012377 drug delivery Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
150000002085 enols Chemical class 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
229940012952 fibrinogen Drugs 0.000 description 1
230000006870 function Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
239000007943 implant Substances 0.000 description 1
230000007574 infarction Effects 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000007919 intrasynovial administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
BRHPBVXVOVMTIQ-ZLELNMGESA-N l-leucine l-leucine Chemical compound CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O BRHPBVXVOVMTIQ-ZLELNMGESA-N 0.000 description 1
238000002430 laser surgery Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000000178 monomer Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000002088 nanocapsule Substances 0.000 description 1
239000002077 nanosphere Substances 0.000 description 1
229920005615 natural polymer Polymers 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
230000000010 osteolytic effect Effects 0.000 description 1
239000006179 pH buffering agent Substances 0.000 description 1
238000010951 particle size reduction Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000008196 pharmacological composition Substances 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
230000000649 photocoagulation Effects 0.000 description 1
238000002428 photodynamic therapy Methods 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920006324 polyoxymethylene Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000026341 positive regulation of angiogenesis Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
208000037803 restenosis Diseases 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
201000003068 rheumatic fever Diseases 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000001488 sodium phosphate Substances 0.000 description 1
229910000162 sodium phosphate Inorganic materials 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
239000000126 substance Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
235000000346 sugar Nutrition 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
230000005945 translocation Effects 0.000 description 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
239000004474 valine Substances 0.000 description 1
125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
238000005406 washing Methods 0.000 description 1
229920003176 water-insoluble polymer Polymers 0.000 description 1
238000009736 wetting Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1
PAPBSGBWRJIAAV-UHFFFAOYSA-N ε-Caprolactone Chemical compound O=C1CCCCCO1 PAPBSGBWRJIAAV-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

ZA200401598A 2001-08-01 2004-02-26 Integrin inhibitors for the treatment of eye diseases. ZA200401598B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US30885101P	2001-08-01	2001-08-01

Publications (1)

Publication Number	Publication Date
ZA200401598B true ZA200401598B (en)	2004-11-17

Family

ID=23195644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200401598A ZA200401598B (en)	2001-08-01	2004-02-26	Integrin inhibitors for the treatment of eye diseases.

Country Status (20)

Country	Link
US (2)	US20040198644A1 (pl)
EP (1)	EP1411926B1 (pl)
JP (1)	JP2005504757A (pl)
KR (1)	KR20040028966A (pl)
CN (1)	CN1536998A (pl)
AR (1)	AR036199A1 (pl)
AT (1)	ATE296628T1 (pl)
AU (1)	AU2002319282B2 (pl)
BR (1)	BR0211604A (pl)
CA (1)	CA2456076C (pl)
DE (1)	DE60204466T2 (pl)
DK (1)	DK1411926T3 (pl)
ES (1)	ES2243744T3 (pl)
HU (1)	HUP0401605A3 (pl)
MX (1)	MXPA04000839A (pl)
PL (1)	PL207175B1 (pl)
PT (1)	PT1411926E (pl)
RU (1)	RU2311177C2 (pl)
WO (1)	WO2003013511A1 (pl)
ZA (1)	ZA200401598B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8293277B2 (en) *	1998-10-01	2012-10-23	Alkermes Pharma Ireland Limited	Controlled-release nanoparticulate compositions
US8236352B2 (en)	1998-10-01	2012-08-07	Alkermes Pharma Ireland Limited	Glipizide compositions
US7198795B2 (en) *	2000-09-21	2007-04-03	Elan Pharma International Ltd.	In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
CA2475092C (en)	2002-02-04	2012-05-01	Baudax Bio, Inc.	Nanoparticulate compositions having lysozyme as a surface stabilizer
EP1667668B1 (en) *	2003-10-01	2008-07-02	MERCK PATENT GmbH	Alfavbeta3 and alfavbeta6 integrin antagonists as antifibrotic agents
EP1856126A2 (en)	2005-02-17	2007-11-21	Wyeth a Corporation of the State of Delaware	Cycloalkylfused indole, benzothiophene, benzofuran and indene derivatives
CN101203505A (zh) *	2005-04-22	2008-06-18	惠氏公司	苯并二氢吡喃和苯并吡喃衍生物及其用途
AU2008321770B2 (en)	2007-11-16	2012-09-06	Ube Industries, Ltd.	Benzazepinone compound
CN102427816A (zh)	2009-03-30	2012-04-25	宇部兴产株式会社	用于治疗或预防眼病的药物组合物
EP2538929A4 (en)	2010-02-25	2014-07-09	Univ Johns Hopkins	DELAYED RELEASE OF THERAPIES IN A PART OF THE EYE
WO2012109363A2 (en)	2011-02-08	2012-08-16	The Johns Hopkins University	Mucus penetrating gene carriers
JP6138904B2 (ja)	2012-03-16	2017-05-31	ザ・ジョンズ・ホプキンス・ユニバーシティー	活性剤の送達のための非線状マルチブロックコポリマー薬物コンジュゲート
US8962577B2 (en)	2012-03-16	2015-02-24	The Johns Hopkins University	Controlled release formulations for the delivery of HIF-1 inhibitors
US8889730B2 (en)	2012-04-10	2014-11-18	Pfizer Inc.	Indole and indazole compounds that activate AMPK
US9533068B2 (en)	2012-05-04	2017-01-03	The Johns Hopkins University	Drug loaded microfiber sutures for ophthalmic application
US20150119792A1 (en) *	2012-05-08	2015-04-30	The Regents Of The University Of California	Light degradable drug delivery system for ocular therapy
WO2014124006A1 (en)	2013-02-05	2014-08-14	The Johns Hopkins University	Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6064062B2 (ja)	2013-03-15	2017-01-18	ファイザー・インク	Ａｍｐｋを活性化させるインダゾール化合物
CN107635545A (zh)	2015-01-27	2018-01-26	约翰霍普金斯大学	用于增强粘膜表面处活性剂的输送的低渗水凝胶制剂
KR101748120B1 (ko) *	2015-07-13	2017-06-16	서울대학교산학협력단	나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
BR112018011278A2 (pt) *	2015-12-04	2018-11-21	Janssen Biotech Inc	tratamento de degeneração da retina com o uso de células progenitoras
KR102506327B1 (ko) *	2016-11-08	2023-03-03	브리스톨-마이어스 스큅 컴퍼니	αV 인테그린 길항제로서의 인다졸 유도체
KR102307767B1 (ko) *	2019-03-11	2021-10-01	서울대학교병원	망막맥락막 신생혈관성 질환을 진단하기 위한 인테그린 αvβ3 표적화 프로브 및 이의 제조 방법
US12496279B2 (en)	2019-04-11	2025-12-16	The Johns Hopkins University	Nanoparticles for drug delivery to brain

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5753230A (en) *	1994-03-18	1998-05-19	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
HUP9802675A3 (en) *	1995-08-14	2000-09-28	Scripps Research Inst	Methods and compositions useful for inhibition of alfa-v beta-5 mediated angiogenesis
DE19538741A1 (de) *	1995-10-18	1997-04-24	Merck Patent Gmbh	Cyclopeptidderivate
US5904144A (en) *	1996-03-22	1999-05-18	Cytotherapeutics, Inc.	Method for treating ophthalmic diseases
CA2256543C (en) *	1996-05-31	2010-12-07	The Scripps Research Institute	Methods and compositions useful for inhibition of angiogenesis
PT951295E (pt) *	1996-05-31	2010-07-29	Scripps Research Inst	COMPOSIÃES PARA UTILIZAÃO NA INIBIÃO DE ANGIOGéNESE MEDIADA POR ALFA-V-BETA3
DE19705450A1 (de) *	1997-02-13	1998-08-20	Merck Patent Gmbh	Bicyclische aromatische Aminosäuren
CN1299278A (zh) *	1998-03-13	2001-06-13	桑道药品有限公司	血管生成抑制
US6489305B1 (en) *	1998-05-08	2002-12-03	Canji, Inc.	Methods and compositions for the treatment of ocular diseases
US6378526B1 (en) *	1998-08-03	2002-04-30	Insite Vision, Incorporated	Methods of ophthalmic administration
DE19850131A1 (de) *	1998-10-30	2000-05-04	Merck Patent Gmbh	Chromenon- und Chromanonderivate
DE10006139A1 (de) *	2000-02-11	2001-08-16	Merck Patent Gmbh	Indol-3-yl-Derivate

2002
- 2002-07-03 PL PL367959A patent/PL207175B1/pl not_active IP Right Cessation
- 2002-07-03 JP JP2003518520A patent/JP2005504757A/ja active Pending
- 2002-07-03 KR KR10-2004-7001509A patent/KR20040028966A/ko not_active Withdrawn
- 2002-07-03 US US10/485,386 patent/US20040198644A1/en not_active Abandoned
- 2002-07-03 HU HU0401605A patent/HUP0401605A3/hu unknown
- 2002-07-03 AT AT02748841T patent/ATE296628T1/de active
- 2002-07-03 MX MXPA04000839A patent/MXPA04000839A/es unknown
- 2002-07-03 DK DK02748841T patent/DK1411926T3/da active
- 2002-07-03 AU AU2002319282A patent/AU2002319282B2/en not_active Ceased
- 2002-07-03 BR BR0211604-9A patent/BR0211604A/pt not_active IP Right Cessation
- 2002-07-03 CA CA2456076A patent/CA2456076C/en not_active Expired - Fee Related
- 2002-07-03 DE DE60204466T patent/DE60204466T2/de not_active Expired - Lifetime
- 2002-07-03 PT PT02748841T patent/PT1411926E/pt unknown
- 2002-07-03 EP EP02748841A patent/EP1411926B1/en not_active Expired - Lifetime
- 2002-07-03 RU RU2004106527/14A patent/RU2311177C2/ru not_active IP Right Cessation
- 2002-07-03 CN CNA028151038A patent/CN1536998A/zh active Pending
- 2002-07-03 WO PCT/EP2002/007377 patent/WO2003013511A1/en not_active Ceased
- 2002-07-03 ES ES02748841T patent/ES2243744T3/es not_active Expired - Lifetime
- 2002-07-31 AR ARP020102892A patent/AR036199A1/es not_active Application Discontinuation
2004
- 2004-02-26 ZA ZA200401598A patent/ZA200401598B/en unknown
2006
- 2006-08-28 US US11/510,596 patent/US7645736B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
DE60204466D1 (de)	2005-07-07
DK1411926T3 (da)	2005-08-29
CN1536998A (zh)	2004-10-13
RU2311177C2 (ru)	2007-11-27
AR036199A1 (es)	2004-08-18
HUP0401605A3 (en)	2012-09-28
DE60204466T2 (de)	2006-04-27
HUP0401605A2 (hu)	2004-11-29
CA2456076C (en)	2011-08-23
ES2243744T3 (es)	2005-12-01
ATE296628T1 (de)	2005-06-15
EP1411926B1 (en)	2005-06-01
US7645736B2 (en)	2010-01-12
JP2005504757A (ja)	2005-02-17
US20040198644A1 (en)	2004-10-07
MXPA04000839A (es)	2004-05-14
RU2004106527A (ru)	2005-07-10
EP1411926A1 (en)	2004-04-28
PL207175B1 (pl)	2010-11-30
US20060287225A1 (en)	2006-12-21
KR20040028966A (ko)	2004-04-03
PT1411926E (pt)	2005-10-31
AU2002319282B2 (en)	2007-06-28
PL367959A1 (pl)	2005-03-07
BR0211604A (pt)	2004-08-24
WO2003013511A1 (en)	2003-02-20
CA2456076A1 (en)	2003-02-20

Publication	Publication Date	Title
EP1411926B1 (en)	2005-06-01	Integrin inhibitors for the treatment of eye diseases
AU2002319282A1 (en)	2003-06-19	Integrin inhibitors for the treatment of eye diseases
US7648959B2 (en)	2010-01-19	Methods and compositions for the treatment of diseases of the eye
US20050085415A1 (en)	2005-04-21	Methods and compositions for the treatment of eye diseases
AU2002238408A1 (en)	2002-08-08	Methods and compositions for the treatment of diseases of the eye
JP2004516254A6 (ja)	2013-02-07	眼の疾患を治療するための方法および組成物
US20040029788A1 (en)	2004-02-12	Methods and compositions for the treatment of diseases of the eye
EP4157238A1 (en)	2023-04-05	Topical ophthalmological compositions and methods for treating abnormal angiogenesis
CN100571772C (zh)	2009-12-23	整联蛋白受体αvβ3和/或αvβ5的拮抗剂在制备用于治疗眼疾的药物中的用途